Nona Biosciences, a subsidiary of HBM Holdings, is at the forefront of innovative therapeutic antibody discovery. With its proprietary Harbour Mice® platform, the company is poised to drive the development of transformative next-generation drugs.

The Harbour Mice® platform is a unique and powerful tool that enables the generation of fully human monoclonal antibodies in both classical two light and two heavy chain (H2L2) format, as well as heavy chain only (HCAb) format. This versatility allows Nona Biosciences to explore a wide range of antibody modalities and unlock the potential of diverse therapeutic targets.

Nona Biosciences' focus on driving global inventions of transformative next-generation drugs is further strengthened by its integrated platform, which encompasses target validation, antibody discovery, and preclinical research. This end-to-end approach allows the company to streamline the drug discovery process and accelerate the development of innovative therapies.

One of the key highlights of Nona Biosciences' recent progress is the signing of two supplemental agreements with Kelun-Biotech, a leading biopharmaceutical company. Under these agreements, Nona Biosciences has licensed two antibody-drug conjugate (ADC) products, developed jointly with Kelun-Biotech, to a third-party for further development and commercialization. Nona Biosciences is entitled to receive 30% of the proceeds, including upfront payments, milestone payments, and tiered royalties, from these collaborations.

This collaboration not only demonstrates the value and recognition of Nona Biosciences' proprietary antibody discovery capabilities but also highlights the company's commitment to providing a comprehensive "Idea to IND" (I to ITM) solution. By leveraging its integrated antibody and antibody-related discovery services, Nona Biosciences is able to support its partners in generating differentiated therapeutic molecules more efficiently and effectively on a global scale.

Dr. Jingsong Wang, the Founder, Chairman, and CEO of Harbour BioMed, expressed his enthusiasm for the collaboration, stating, "We are glad to achieve in-depth cooperation with Kelun-Biotech, which is also a powerful recognition of our proprietary H2L2 platform. Leveraging the Harbour Mice® platform together with our antibody discovery capabilities, we look forward to helping our partners generate differentiated therapeutic molecules more and better on a global basis."

Nona Biosciences' innovative approach to therapeutic antibody discovery is not limited to its partnerships. The company also continues to invest in its own internal pipeline, exploring various therapeutic areas and leveraging the versatility of the Harbour Mice® platform to identify and develop promising drug candidates.

In conclusion, Nona Biosciences' innovative antibody discovery strategies, anchored by the Harbour Mice® platform, are enabling the company to forge strategic collaborations, drive global inventions of transformative next-generation drugs, and position itself as a leader in the field of therapeutic antibody discovery.